Trial started· ClinicalTrials.gov
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Chemotherapy Prior to RAPA-201 Therapy History and Updates
9 events · 2019 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
0
FDA Approvals
0
Label Revisions
9
Trial Milestones
0
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-05-08Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Chemotherapy Prior to RAPA-201 Therapy since 2019, drawn from openFDA, ClinicalTrials.gov, and PubMed.
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Past events
2026
Primary completion· ClinicalTrials.gov
RAPA-201 Therapy of Solid Tumors
2024
Trial registered· ClinicalTrials.gov
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
2023
Primary completion· ClinicalTrials.gov
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
2021
Trial registered· ClinicalTrials.gov
RAPA-201 Therapy of Solid Tumors
Trial started· ClinicalTrials.gov
RAPA-201 Therapy of Solid Tumors
2020
Trial started· ClinicalTrials.gov
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
2019
Trial registered· ClinicalTrials.gov
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.